PBYI (PUMA BIOTECHNOLOGY INC)
Insider Trading Activity
Every open-market purchase and sale reported by PBYI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2026-07-08 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| 2026-07-08 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2026-06-15 | Alessandra Cesano | Director | A | — | — |
| 2026-06-15 | JAY M MOYES | Director | MIXED | — | — |
| 2026-06-15 | Adrian Senderowicz | Director | MIXED | — | — |
| 2026-06-15 | Allison Dorval | Director | MIXED | — | — |
| 2026-06-15 | MICHAEL PATRICK MILLER | Director | A | — | — |
| 2026-06-15 | TROY EDWARD WILSON | Director | MIXED | — | — |
| 2026-06-15 | Brian M Stuglik | Director | MIXED | — | — |
| 2026-02-20 | DOUGLAS M HUNT | See Remarks | A | — | — |
| 2026-02-20 | ALAN H AUERBACH | President and CEO | A | — | — |
| 2026-02-20 | MAXIMO F NOUGUES | Chief Financial Officer | A | — | — |
| 2026-01-08 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2026-01-08 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| 2026-01-08 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2025-11-13 | MICHAEL PATRICK MILLER | Director | Sell | — | — |
| 2025-07-22 | Alessandra Cesano | Director | Sell | — | — |
| 2025-07-10 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2025-07-10 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2025-07-10 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| 2025-06-17 | Brian M Stuglik | Director | Sell | — | — |
| 2025-06-17 | Allison Dorval | Director | Sell | — | — |
| 2025-06-17 | JAY M MOYES | Director | Sell | — | — |
| 2025-06-17 | Adrian Senderowicz | Director | Sell | — | — |
| 2025-06-17 | Alessandra Cesano | Director | Sell | — | — |
| 2025-06-17 | TROY EDWARD WILSON | Director | Sell | — | — |
| 2025-06-13 | Brian M Stuglik | Director | A | — | — |
| 2025-06-13 | MICHAEL PATRICK MILLER | Director | A | — | — |
| 2025-06-13 | JAY M MOYES | Director | A | — | — |
| 2025-06-13 | Alessandra Cesano | Director | A | — | — |
| 2025-06-13 | Allison Dorval | Director | A | — | — |
| 2025-06-13 | Adrian Senderowicz | Director | A | — | — |
| 2025-06-13 | TROY EDWARD WILSON | Director | A | — | — |
| 2025-02-11 | MAXIMO F NOUGUES | Chief Financial Officer | A | — | — |
| 2025-02-11 | ALAN H AUERBACH | President and CEO | A | — | — |
| 2025-02-11 | DOUGLAS M HUNT | See Remarks | A | — | — |
| 2025-02-11 | Jeffrey Jerome Ludwig | Chief Commercial Officer | A | — | — |
| 2025-01-03 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2025-01-03 | Jeffrey Jerome Ludwig | Chief Commercial Officer | Sell | — | — |
| 2025-01-03 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2025-01-03 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| 2024-08-13 | MICHAEL PATRICK MILLER | Director | Sell | — | — |
| 2024-07-18 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2024-07-18 | Jeffrey Jerome Ludwig | Chief Commercial Officer | Sell | — | — |
| 2024-07-18 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| 2024-07-18 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2024-07-02 | ALAN H AUERBACH | President and CEO | Sell | — | — |
| 2024-07-02 | DOUGLAS M HUNT | See Remarks | Sell | — | — |
| 2024-07-02 | MAXIMO F NOUGUES | Chief Financial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 7,261,671 | — |
| — | 10%+ Owner | 5,491,653 | — |
| — | 10%+ Owner | 5,192,959 | — |
| — | 10%+ Owner | 4,010,607 | — |
| — | 10%+ Owner | 3,854,302 | — |
| — | Director | 600,993 | — |
| — | Chief Financial Officer | 230,637 | — |
| — | See Remarks | 196,841 | — |
| — | Chief Commercial Officer | 156,792 | — |
| — | Director | 156,551 | — |
| — | Chief Scientific Officer | 141,241 | — |
| — | Director | 121,958 | — |
| — | SEE REMARKS | 121,662 | — |
| — | Director | 102,390 | — |
| — | Director | 81,000 | — |
| — | Director | 70,950 | — |
| — | Director | 68,850 | — |
| — | Director | 58,322 | — |
| — | Director | 40,732 | — |
| — | SEE REMARKS | 31,957 | — |
| — | Director | 27,000 | — |
| — | See Remarks | 26,453 | — |
| — | Director | 25,748 | — |
| — | Chief Commercial Officer | 19,557 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PBYI quote page; the site-wide leaderboard is on the insider transactions hub.